In:
Science Translational Medicine, American Association for the Advancement of Science (AAAS), Vol. 16, No. 741 ( 2024-04-03)
Abstract:
Tissue fibrosis underlies many chronic diseases that are difficult to treat. Transforming growth factor-β (TGFβ) regulates fibrosis, but it is also involved in other processes, making it difficult to target. Pan et al. showed that human fibrotic tissue had increased Mer tyrosine kinase (MERTK), a TGFβ effector. MERTK acted downstream of and in a positive feedback loop with TGFβ in human and mouse cells to promote fibrotic signaling. In mouse models of liver, kidney, and lung fibrosis, genetic deletion of Mertk prevented fibrosis. A pharmacologic inhibitor of MERTK reduced fibrosis in these models and in an additional mouse model of liver fibrosis. These data suggest that fibrosis could be treated by MERTK inhibition. —Brandon Berry
Type of Medium:
Online Resource
ISSN:
1946-6234
,
1946-6242
DOI:
10.1126/scitranslmed.adj0133
Language:
English
Publisher:
American Association for the Advancement of Science (AAAS)
Publication Date:
2024
detail.hit.zdb_id:
2518839-2
detail.hit.zdb_id:
2518854-9
Permalink